Keros Therapeutics KROS 深 滬
已收盤 02-06 16:00:00 美东时间
17.57
+0.330
+1.91%
華盛通- 最 高17.90
- 今 開17.45
- 成交量 30.55万股
- 最 低 17.35
- 昨 收 17.24
- 總市值 5.35亿
- 52周最高 22.55
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 9.12
- 委 比 71.79%
- 總股本 3046.61万
- 歷史最高 88.80
- 量 比 1.13
- 振 幅 3.19%
- 歷史最低 9.12
- 每 手 1
- 風險率 2.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
2025-12-01 14:33
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19
B of A Securities analyst Jason Zemansky maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $18 to $19.
2025-11-29 01:08
Keros Therapeutics Announces Preliminary Results of Tender Offer
Keros Therapeutics, Inc. announced preliminary results of its cash tender offer, repurchasing up to 10,950,165 shares at $17.75 per share, totaling $194.4 million. The offer expired on November 18, 2025, concluding its $375 million capital return program. Approximately 16,659,732 shares were validly tendered, with 1,186,829 shares tendered via guaranteed delivery. Due to excess submissions, shares will be accepted on a pro rata basis. This marks ...
2025-11-19 11:00
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16
Wedbush analyst Yun Zhong maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $15 to $16.
2025-11-06 21:35
Keros Therapeutics Q3 EPS $(0.18) Beats $(1.05) Estimate, Sales $14.262M Beat $3.800M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(1.05) by 82.81 percent. This is a 87.23 percent increase over losses of $(1.41) per share
2025-11-06 06:04
Keros宣布启动要约回购最多1.944亿美元股票计划
美股周一早盘，临床阶段药物开发商Keros Therapeutics（KROS）上涨2.1%，此前该公司宣布启动要约回购最多1.944亿美元自身股票。此举是...
2025-10-20 21:55
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares
Keros Therapeutics (NASDAQ:KROS) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per share. The Company expects to fund the tender ...
2025-10-20 18:26
